FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165568315> ?p ?o ?g. }

• W3165568315 endingPage "4741" @default.
• W3165568315 startingPage "4733" @default.
• W3165568315 abstract "The hepatitis B virus is highly infectious and can cause incurable liver disease, leading to high morbidity rates, increased healthcare utilization, and high mortality. Multiple preventative hepatitis B vaccine options have been available for decades, but adherence to the traditional 6-month vaccine schedule for the approved 3-dose series remains low in adult populations at risk of hepatitis B exposure. A 2-dose hepatitis B vaccine (HEPLISAV-B) approved by the US Food and Drug Administration in 2017 induces rapid seroprotection within 1 month and has a safety profile comparable to a commonly used 3-dose vaccine. In a previous cost-effectiveness study, HEPLISAV-B had a favorable cost-effectiveness profile for multiple at-risk populations. The goal of the current analysis was to update and extend previous findings by evaluating cost-effectiveness of HEPLISAV-B compared with a 3-dose vaccine (Engerix-B) in selected adult populations, including patients with diabetes, chronic liver or kidney disease, end-stage renal disease, healthcare personnel, travelers to countries with endemic hepatitis B, and a public health population. Cost-effectiveness was measured as incremental cost-effectiveness ratios using a health economics Markov model that accounts for adherence rates, seroprotection rates, healthcare costs, and current pricing considerations. Patients progressed between a series of health states, and the difference in lifetime spending and survival for individuals receiving either HEPLISAV-B or Engerix-B was estimated from the perspective of a US managed care payer, HEPLISAV-B had favorable cost-effectiveness profiles for patients with diabetes, healthcare personnel, travelers, and patients with chronic liver disease and dominant incremental cost-effectiveness ratios for patients with chronic kidney disease and end-stage renal disease. A probabilistic sensitivity analysis supported the robustness of the cost-effectiveness profiles, and an additional analysis indicated that HEPLISAV-B was cost-effective in the general adult population. Overall, HEPLISAV-B was cost-effective in multiple adult populations recommended for HBV vaccination in the United States." @default.
• W3165568315 created "2021-06-07" @default.
• W3165568315 creator A5022554316 @default.
• W3165568315 creator A5061431964 @default.
• W3165568315 creator A5064284912 @default.
• W3165568315 date "2021-07-01" @default.
• W3165568315 modified "2023-09-27" @default.
• W3165568315 title "Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations" @default.
• W3165568315 cites W1016679971 @default.
• W3165568315 cites W104623139 @default.
• W3165568315 cites W1965807091 @default.
• W3165568315 cites W1967057471 @default.
• W3165568315 cites W1984344671 @default.
• W3165568315 cites W2001550129 @default.
• W3165568315 cites W2007332701 @default.
• W3165568315 cites W2019444858 @default.
• W3165568315 cites W2020294125 @default.
• W3165568315 cites W2023740236 @default.
• W3165568315 cites W2029837112 @default.
• W3165568315 cites W2043050344 @default.
• W3165568315 cites W2044246489 @default.
• W3165568315 cites W2045295189 @default.
• W3165568315 cites W2046636568 @default.
• W3165568315 cites W2048843683 @default.
• W3165568315 cites W2059749879 @default.
• W3165568315 cites W2070046531 @default.
• W3165568315 cites W2071476028 @default.
• W3165568315 cites W2072706410 @default.
• W3165568315 cites W2085067074 @default.
• W3165568315 cites W2085830539 @default.
• W3165568315 cites W2086581349 @default.
• W3165568315 cites W2087564721 @default.
• W3165568315 cites W2088227275 @default.
• W3165568315 cites W2091179205 @default.
• W3165568315 cites W2100090302 @default.
• W3165568315 cites W2103762134 @default.
• W3165568315 cites W2125306655 @default.
• W3165568315 cites W2128428904 @default.
• W3165568315 cites W2144641242 @default.
• W3165568315 cites W2146085139 @default.
• W3165568315 cites W2146461887 @default.
• W3165568315 cites W2158446994 @default.
• W3165568315 cites W2164668044 @default.
• W3165568315 cites W2306356166 @default.
• W3165568315 cites W2404338841 @default.
• W3165568315 cites W2467253658 @default.
• W3165568315 cites W2494403447 @default.
• W3165568315 cites W2513247606 @default.
• W3165568315 cites W2767733906 @default.
• W3165568315 cites W2779802669 @default.
• W3165568315 cites W2800687120 @default.
• W3165568315 cites W2808856055 @default.
• W3165568315 cites W2893274270 @default.
• W3165568315 cites W2898791146 @default.
• W3165568315 cites W2900951286 @default.
• W3165568315 cites W2911619082 @default.
• W3165568315 cites W2921382011 @default.
• W3165568315 cites W2953833210 @default.
• W3165568315 cites W2968330541 @default.
• W3165568315 cites W2977532127 @default.
• W3165568315 cites W2981421482 @default.
• W3165568315 cites W3094697606 @default.
• W3165568315 cites W995766038 @default.
• W3165568315 doi "https://doi.org/10.1016/j.vaccine.2021.05.020" @default.
• W3165568315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34030898" @default.
• W3165568315 hasPublicationYear "2021" @default.
• W3165568315 type Work @default.
• W3165568315 sameAs 3165568315 @default.
• W3165568315 citedByCount "7" @default.
• W3165568315 countsByYear W31655683152021 @default.
• W3165568315 countsByYear W31655683152022 @default.
• W3165568315 countsByYear W31655683152023 @default.
• W3165568315 crossrefType "journal-article" @default.
• W3165568315 hasAuthorship W3165568315A5022554316 @default.
• W3165568315 hasAuthorship W3165568315A5061431964 @default.
• W3165568315 hasAuthorship W3165568315A5064284912 @default.
• W3165568315 hasBestOaLocation W31655683151 @default.
• W3165568315 hasConcept C112930515 @default.
• W3165568315 hasConcept C126322002 @default.
• W3165568315 hasConcept C138816342 @default.
• W3165568315 hasConcept C159110408 @default.
• W3165568315 hasConcept C160735492 @default.
• W3165568315 hasConcept C162324750 @default.
• W3165568315 hasConcept C177713679 @default.
• W3165568315 hasConcept C203014093 @default.
• W3165568315 hasConcept C2522874641 @default.
• W3165568315 hasConcept C2777382497 @default.
• W3165568315 hasConcept C2777410769 @default.
• W3165568315 hasConcept C2780593183 @default.
• W3165568315 hasConcept C2781037505 @default.
• W3165568315 hasConcept C2908647359 @default.
• W3165568315 hasConcept C3019080777 @default.
• W3165568315 hasConcept C50522688 @default.
• W3165568315 hasConcept C515549039 @default.
• W3165568315 hasConcept C71924100 @default.
• W3165568315 hasConcept C99454951 @default.
• W3165568315 hasConceptScore W3165568315C112930515 @default.
• W3165568315 hasConceptScore W3165568315C126322002 @default.

• next